The International Pharmaceutical Excipients Council Federation, (IPEC Federation) announces the availability of the revised IPEC Incorporation of Pharmaceutical Excipients into Product Development using Quality-by-Design (QbD) (Version 2, 2025).
The guide was first published as an IPEC Federation guide in 2020; however, with this revision, the guide has been updated to include an annex incorporating contents from the 2016 IPEC-Americas QbD Sampling Guide.
This guide is widely applicable globally.
The primary goal of the QbD guide is to
This Guide includes recommendations related to the impact of excipient variability on drug product quality during development and to justify management of excipient variability in the control strategy. It contains useful explanations and suggestions for pharmaceutical excipient makers and users.
The Guide is applicable to excipient use throughout the pharmaceutical product development process using a Quality by Design (QbD) approach described by the International Conference on Harmonization (ICH) Q8 as well as other applicable ICH Guidelines such as ICH Q9, Q10, Q11, Q12 and Q13.
The guide will be available, initially exclusively to IPEC members for a three-month period, on the IPEC Federation and national/regional members’ websites. Thereafter, the guide will be made available to the general public.